Piroxicam Premedication for Postendodontic Pain in Non-vital Mandibular Molars

Launched by CAIRO UNIVERSITY · Jun 25, 2019

Keywords

ClinConnect Summary

* Patients will be clinically and radiographically examined and their eligibility will be assessed. Eligible patients will be treated in one visit.
* Patients will be randomly assigned to one of 2 groups: experimental group (premedication with 20 mg of piroxicam) and the control group (premedication with placebo). Each participant will receive a standard inferior alveolar nerve block injection. After endodontic treatment, patients will be given postoperative instructions and informed, in case of pain, to receive ibuprofen 200 mg as rescue medication.
* Postendodontic pain intensity and inci...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients aging between 18-50 years old
• • 2. Patients with mandibular molar with non-vital pulp.
• • 3. Systemically- healthy patients (ASA I or II).
• • 4. Patients who agree to attend for recall appointments and provide a written consent.
• Exclusion Criteria:
• • 1. Pregnant or lactating female patients.
• • 2. Patients allergic to piroxicam.
• • 3. History of peptic ulceration.
• • 4. Periapical abscess, fistula.
• • 5. Non-restorable teeth.
• • 6. Moderate or severe marginal periodontitis i.e. pocket probe\>3mm.